Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Karyopharm Therapeutics Stock Performance
KPTI Stock traded down $0.30 during midday trading on Tuesday, reaching $4.86. The company had a trading volume of 71,135 shares, compared to its average volume of 1,956,156. The stock has a 50 day moving average price of $4.95 and a 200 day moving average price of $6.72. Karyopharm Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $14.73.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $17.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday. Barclays decreased their price target on Karyopharm Therapeutics from $14.00 to $8.00 and set an "overweight" rating for the company in a research note on Friday. Canaccord Genuity Group cut their price objective on Karyopharm Therapeutics from $20.00 to $10.00 in a research note on Monday, April 11th. Finally, HC Wainwright decreased their target price on Karyopharm Therapeutics from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Friday. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of "Hold" and an average target price of $10.25.
Insider Buying and Selling
In related news, Director Deepika Pakianathan sold 325,977 shares of the company's stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $6.50, for a total transaction of $2,118,850.50. Following the completion of the transaction, the director now directly owns 18,731 shares in the company, valued at approximately $121,751.50. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have sold 336,407 shares of company stock valued at $2,174,368. Insiders own 10.24% of the company's stock.